These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


993 related items for PubMed ID: 25070304

  • 21. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
    Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, Kimpen JL, Palivizumab Long-Term Respiratory Outcomes Study Group.
    J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
    Lacaze-Masmonteil T, Rozé JC, Fauroux B, French Pediatricians' Group of Sunagis Patients' Name-Based Programs.
    Pediatr Pulmonol; 2002 Sep; 34(3):181-8. PubMed ID: 12203846
    [Abstract] [Full Text] [Related]

  • 28. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
    Resch B, Sommer C, Nuijten MJ, Seidinger S, Walter E, Schoellbauer V, Mueller WD.
    Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
    [Abstract] [Full Text] [Related]

  • 29. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
    Frogel M, Nerwen C, Boron M, Cohen A, VanVeldhuisen P, Harrington M, Groothuis J, Palivizumab Outcomes Registry Group.
    Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
    [Abstract] [Full Text] [Related]

  • 30. Economic analysis of palivizumab in infants with congenital heart disease.
    Yount LE, Mahle WT.
    Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
    [Abstract] [Full Text] [Related]

  • 31. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
    Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M, Palivizumab Outcomes Registry Group.
    J Perinatol; 2008 Jul; 28(7):511-7. PubMed ID: 18368063
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.
    Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, Connor EM, Sondheimer HM, Cardiac Synagis Study Group.
    J Pediatr; 2003 Oct; 143(4):532-40. PubMed ID: 14571236
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season.
    Singleton RJ, Bruden D, Bulkow LR, Varney G, Butler JC.
    Pediatr Infect Dis J; 2006 Dec; 25(12):1116-22. PubMed ID: 17133156
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Nosocomial respiratory syncytial virus infections in the palivizumab-prophylaxis era with implications regarding high-risk infants.
    Ashkenazi-Hoffnung L, Dotan M, Livni G, Amir J, Bilavsky E.
    Am J Infect Control; 2014 Sep; 42(9):991-5. PubMed ID: 25179332
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 50.